Publications

Subgroup-SHH of medulloblastoma (MB) is primarily found in children, with an increased propensity for metastatic presentation that contributes to its poor prognosis. Current therapy approaches may include surgery, radiation, systematic chemotherapy, and autologous stem cell[...]

Childhood cancer arises from disrupted developmental processes driven by genetic and epigenetic changes, making them fundamentally different from adult malignancies. Understanding this unique biology requires models that faithfully capture the complexity of pediatric cancer. Patient-derived[...]

Smith KH, Trovillion EM, McKinney KQ, Gourabathini P, Wells K, Gandra D, Sholler C, Votruba I, Oesterheld J, Saulnier Sholler GL. In Vitro and In Vivo Efficacy of Romidepsin Alone and in Addition to Standard of[...]

Osteosarcoma is the most common type of primary malignant bone tumor in children, adolescents and young adults and remains a significant clinical challenge, especially in the context of metastatic disease. Here we report the case[...]

Approved treatments for patients with refractory and/or relapsed (R/R) high-risk (HR) neuroblastoma are limited, and there is a need for new treatment combinations. In this case series, 4 patients were treated with the anti-GD2 monoclonal[...]

Neuroblastoma is a common childhood malignancy, and high-risk presentations, including an MYCN amplified status, continue to result in poor survival. Difluoromethylornithine (DFMO) is a new and well-tolerated treatment for high-risk neuroblastoma. This review article discusses[...]